Summary
PROJECT SUMMARY Synthetic biology is driving a new era of medicine through the genetic programming of living cells. One particular focus has been the engineering of bacteria as therapeutic delivery systems to selectively release therapeutic payloads in vivo. Since colorectal cancer (CRC) initiation and progression are significantly influenced by interactions between intestinal microbes and the mucosal immune system, these interactions can be specifically modulated with engineered probiotics for immoprevention and interception. Our laboratories have demonstrated that a probiotic bacteria, E. c
